FDA approves Replimune melanoma drug previously rejected twice
FDA approves Replimune melanoma drug previously rejected twice STAT
2026
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy…